Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions.
Aggrecanase cleavage at the Glu(373)-Ala(374) site in the interglobular domain of the cartilage proteoglycan aggrecan is a key event in arthritic diseases. The observation that substrates representing only the aggrecanase cleavage site are not catabolized efficiently by aggrecanase prompted us to investigate the requirement of aggrecanase for additional structural elements of its substrate other than the actual cleavage site. Based on the recombinant substrate rAgg1mut we constructed deletion mutants with successively truncated N- or C-termini of the interglobular domain. Catabolism by aggrecanase activities induced in rat chondrosarcoma cells, porcine chondrocytes, and by human recombinant ADAMTS4 showed a gradually decreasing catabolism of progressively shortened, N-terminal deletion mutants of the substrate rAgg1mut. A reduction to 32 amino acids N-terminal to the aggrecanase site resulted in a decrease of at least 42% of aggrecanase cleavage products as compared with the wild-type substrate. When only 16 amino acids preceded the Glu(373)-Ala(374) site, aggrecanase cleavage was completely inhibited. In contrast, C-terminal deletions did not negatively affect aggrecanase cleavage up to the reduction to 13 amino acids C-terminal to the cleavage site. Unlike aggrecanase(s), membrane type 1-matrix metalloprotease (MT1-MMP), able to cleave rAgg1mut both at the aggrecanase and the MMP site, was insensitive to N-terminal deletions regarding aggrecanase cleavage, indicating that the importance of the N-terminus is characteristic for aggrecanase(s). Taken together, the results demonstrate that the amino-terminus of rAgg1mut, containing the MMP site, plays an important role for efficient cleavage by aggrecanase(s), possibly by serving as a further site of interaction between the enzyme and its substrate.
Hörber
C
C
From the Disease Group Thrombotic Diseases & Degenerative Joint Diseases, Aventis Pharma Deutschland GmbH, Industriepark Hoechst, H 825, 65926, Frankfurt, Germany.
Büttner
F H
FH
Kern
C
C
Schmiedeknecht
G
G
Bartnik
E
E
D051722:ADAM Proteins; D000071121:ADAMTS4 Protein; D053674:Aggrecans; D000595:Amino Acid Sequence; D000818:Animals; D002478:Cells, Cultured; D010450:Endopeptidases / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D016326:Extracellular Matrix Proteins; D006801:Humans; D007074:Immunoglobulin G / Q000235:genetics / Q000302:isolation & purification; D037181:Lectins, C-Type; D053504:Matrix Metalloproteinases, Membrane-Associated; D008666:Metalloendopeptidases / Q000378:metabolism; D008969:Molecular Sequence Data; D009842:Oligopeptides; D010455:Peptides / Q000235:genetics / Q000302:isolation & purification; D011348:Procollagen N-Endopeptidase; D011509:Proteoglycans / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism*; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000302:isolation & purification / Q000378:metabolism; D017384:Sequence Deletion; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured
C508321:Acan protein, rat; D053674:Aggrecans; D016326:Extracellular Matrix Proteins; D007074:Immunoglobulin G; D037181:Lectins, C-Type; D009842:Oligopeptides; D010455:Peptides; D011509:Proteoglycans; D011993:Recombinant Fusion Proteins; C085706:FLAG peptide; D010450:Endopeptidases; D051722:ADAM Proteins; D053504:Matrix Metalloproteinases, Membrane-Associated; D008666:Metalloendopeptidases; D011348:Procollagen N-Endopeptidase; D000071121:ADAMTS4 Protein; C000603918:ADAMTS4 protein, human; C083641:aggrecanase